Phase 2 N=161 Tau Screening Study in Subjects With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 51; 13; 1; 65 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=155 Tau Screening Study in Patients With Early Symptomatic AD
Alzheimer Disease
Primary: Flortaucipir Qualitative Results (Visual Reads) — 56; 22; 78; 2 Participants
Phase 2 N=57 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
Phase 2 N=16 Pharmacokinetics of Advantage Anti-Caries Varnish
Dental Caries
Primary: Observed Iodine Tmax — 1.7 hours
Phase 2 N=37 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 — 2; 18; 14; 1 Participants
Phase 2 N=392 A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Non-alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis · NASH - Nonalcoholic Steatohepatitis
Primary: Number of Participants With Hepatic Histological Improvement in NAS — 22; 25; 27; 34 Participants — p=0.747
Phase 2 N=124 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
Phase 2 N=19 Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Rate of Complete Response as Determined by the IMWG Criteria — 2 Participants
Phase 2 N=50 Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete…
Phase 2 N=128 Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain
Constipation
Primary: Percentage of Participants Witn Spontaneous Bowel Movements Within 3 Hours of Treatment — 2; 3; 2; 5 Participants
Phase 2 N=154 Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Psoriasis
Primary: Percent of Subjects With Treatment Success — 32.79; 33.97; 0; 7.14 percentage of participants
Phase 2 N=130 A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Adenocarcinoma of the Lung
Primary: Progression-free Survival (PFS) — 5.8; 4.7; 5.9; 4.7 Months — p=0.3519
Phase 2 N=212 Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 8 — 52.5; 33.3…
Phase 2 N=152 Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Psoriasis
Primary: Percent of Subjects With Treatment Success, Defined by at Least a 2 Grade Improvement From Baseline in the Investigator Global Assessment (IGA) Score Equating to Clear…
Phase 2 N=99 Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Hematologic Malignancy · Myeloproliferative Disorder
Primary: Clinical Failure of Isavuconazole Prophylaxis by Week + 14 Post Hematopoietic Stem Cell Transplant (HCT) — 81; 3; 7; 4 Participants